CORE
CO
nnecting
RE
positories
Services
Services overview
Explore all CORE services
Access to raw data
API
Dataset
FastSync
Content discovery
Recommender
Discovery
OAI identifiers
OAI Resolver
Managing content
Dashboard
Bespoke contracts
Consultancy services
Support us
Support us
Membership
Sponsorship
Research partnership
About
About
About us
Our mission
Team
Blog
FAQs
Contact us
Community governance
Governance
Advisory Board
Board of supporters
Research network
Innovations
Our research
Labs
Antiangiogenic Drugs in the Treatment of Diabetic Macular Edema
Authors
Mavlonov N. X.
Publication date
16 December 2023
Publisher
Academic Journal Inc
Doi
Abstract
The article presents the characteristics of the first antiangiogenic drug registered for the treatment of diabetic macular edema, ranibizumab, as well as the new long-acting drug brolucizumab
Similar works
Full text
Open in the Core reader
Download PDF
Available Versions
Academic Journal Inc.
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:ojs2.inter-publishing.com:...
Last time updated on 28/06/2024
Academic Journal Inc.
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:ojs2.inter-publishing.com:...
Last time updated on 28/06/2024
